Skip to main content
TipRanks
Go Ultimate75% OFF

Eli Lilly & Co (LLY) Revenue by Segment

23,967 Followers

Revenue by Segment

In Q3 2026, Eli Lilly & Co reported revenue by segment of $154.00M (Other), $444.00M (Neuroscience), $2.60B (Oncology), $1.44B (Immunology) and $19.76B (Cardiometabolic).

Splits sales by business lines or therapy areas to reveal whether Lilly’s growth is driven by a few blockbuster drugs or a diversified portfolio. Helps investors assess product concentration risk, the impact of new launches, and which segments are likely to sustain revenue and profit expansion.

$0.00$5.00B$10.00B$15.00B$20.00B$25.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Cardiometabolic has become the dominant growth engine, driving a structural shift in Lilly’s revenue mix and underpinning the company’s guidance and margin upgrade; Oncology and Immunology provide steady, compounding support rather than the spike, while Neuroscience and Other are comparatively muted. Q2 commercial scale (Mounjaro/Zepbound) validates the upside, but monitor near‑term risks — U.S. price/rebate pressure, launch noise (Foundayo) and retatrutide regulatory timing — that could slow percentage growth or compress net pricing despite rising volume.

LLY Revenue by Segment

PeriodOtherCardiovascularNeuroscienceOncologyImmunologyAnimal HealthCardiometabolic
Q3 2026Sep 30, 2026$154.00M$0.00$444.00M$2.60B$1.44B$0.00$19.76B
Q2 2026Jun 30, 2026$205.00M$0.00$429.00M$2.57B$1.42B$0.00$18.35B
Q1 2026Mar 31, 2026$187.00M$0.00$382.00M$2.27B$1.20B$0.00$15.76B
Q4 2025Dec 31, 2025$191.40M$0.00$459.20M$2.61B$1.54B$0.00$14.49B
Q3 2025Sep 30, 2025$337.20M$0.00$315.70M$2.41B$1.36B$0.00$13.18B
Q2 2025Jun 30, 2025$201.50M$0.00$344.00M$2.41B$1.26B$0.00$11.34B
Q1 2025Mar 31, 2025$212.90M$0.00$272.10M$1.95B$1.09B$0.00$9.21B
Q4 2024Dec 31, 2024$190.60M$0.00$393.10M$2.55B$1.29B$0.00$9.11B
Q3 2024Sep 30, 2024$262.80M$0.00$351.80M$2.23B$1.19B$0.00$7.41B
Q2 2024Jun 30, 2024$207.60M$0.00$339.50M$2.16B$1.08B$0.00$7.51B
Q1 2024Mar 31, 2024$241.90M$0.00$389.10M$1.81B$834.00M$0.00$5.49B
Q4 2023Dec 31, 2023$256.20M$0.00$362.70M$1.88B$1.10B$0.00$5.75B
Q3 2023Sep 30, 2023$276.10M$0.00$1.77B$1.75B$986.90M$0.00$4.72B
Q2 2023Jun 30, 2023$314.60M$0.00$387.20M$1.67B$928.50M$0.00$5.01B
Q1 2023Mar 31, 2023$275.30M$0.00$360.50M$1.36B$777.80M$0.00$4.19B
Q4 2022Dec 31, 2022$355.90M$0.00$385.30M$1.65B$933.60M$0.00$3.98B
Q3 2022Sep 30, 2022$746.00M$0.00$373.20M$1.29B$866.40M$0.00$3.66B
Q2 2022Jun 30, 2022$494.70M$0.00$389.90M$1.37B$796.50M$0.00$3.44B
Q1 2022Mar 31, 2022$1.92B$0.00$397.70M$1.35B$748.10M$0.00$3.39B
Q4 2021Dec 31, 2021$1.54B$0.00$470.60M$1.41B$956.50M$0.00$3.63B
Q3 2021Sep 30, 2021$637.70M$0.00$450.20M$1.41B$1.00B$0.00$3.27B
Q2 2021Jun 30, 2021$712.90M$0.00$512.20M$1.55B$785.40M$0.00$3.18B
Q1 2021Mar 31, 2021$1.24B$0.00$465.40M$1.37B$613.90M$0.00$3.11B
Q4 2020Dec 31, 2020$1.45B$0.00$474.60M$1.52B$700.70M$0.00$3.30B
Q3 2020Sep 30, 2020$526.40M$0.00$470.70M$1.33B$627.10M$0.00$2.78B
Q2 2020Jun 30, 2020$481.00M$0.00$422.50M$1.27B$548.30M$0.00$2.78B
Q1 2020Mar 31, 2020$640.10M$0.00$463.50M$1.20B$585.50M$0.00$2.97B
Q4 2019Dec 31, 2019$326.00M$0.00$450.30M$1.26B$547.90M$0.00$3.53B
Q3 2019Sep 30, 2019$303.50M$0.00$426.70M$1.15B$454.60M$0.00$3.14B
Q2 2019Jun 30, 2019$323.50M$0.00$452.70M$1.20B$456.10M$0.00$3.21B
Q1 2019Mar 31, 2019$421.60M$0.00$393.10M$1.01B$334.70M$0.00$2.93B
Q4 2018Dec 31, 2018$46.40M$408.60M$449.80M$1.13B$377.10M$816.50M$3.21B
Q3 2018Sep 30, 2018$56.60M$583.80M$427.20M$1.06B$319.50M$772.70M$2.84B
Q2 2018Jun 30, 2018$69.50M$693.00M$471.00M$1.11B$264.70M$792.10M$2.95B
Q1 2018Mar 31, 2018$70.50M$561.50M$472.70M$956.60M$178.70M$761.30M$2.97B
Q4 2017Dec 31, 2017$56.80M$698.70M$497.30M$1.01B$195.50M$790.90M$2.91B
Q3 2017Sep 30, 2017$61.00M$662.90M$507.70M$957.60M$167.60M$740.60M$2.56B
Q2 2017Jun 30, 2017$49.60M$812.40M$586.70M$955.90M$143.50M$784.80M$2.49B
Q1 2017Mar 31, 2017$73.80M$697.20M$579.30M$887.00M$98.50M$769.40M$2.12B
Q4 2016Dec 31, 2016$39.30M$870.40M$650.40M$909.50M$61.30M$837.60M$2.39B
Q3 2016Sep 30, 2016$47.90M$773.50M$708.50M$947.30M$32.50M$706.20M$1.98B
Q2 2016Jun 30, 2016$51.80M$827.30M$717.70M$970.50M$19.30M$859.80M$1.96B
Q1 2016Mar 31, 2016$61.40M$754.20M$643.70M$894.50M$0.00$754.60M$1.76B

Related KPIs